Facts and hopes on chimeric cytokine agents for cancer immunotherapy

Clin Cancer Res. 2024 Jan 8. doi: 10.1158/1078-0432.CCR-23-1160. Online ahead of print.ABSTRACTCytokines are key mediators of immune responses that can modulate the antitumor activity of immune cells. Cytokines have been explored as a promising cancer immunotherapy. However, there are several challenges to cytokine therapy, especially a lack of tumor targeting, resulting in high toxicity and limited efficacy. To overcome these limitations, novel approaches have been developed to engineer cytokines with improved properties, such as chimeric cytokines. Chimeric cytokines are fusion proteins that combine different cytokine domains or link cytokines to antibodies (immunocytokines) or other molecules that can target specific receptors or cells. Chimeric cytokines can enhance the selectivity and stability of cytokines, leading to reduced toxicity and improved efficacy. In this review, we focus on two promising cytokines, interleukin-2 (IL-2) and IL-15, and summarize the current advances and challenges of chimeric cytokine design and application for cancer immunotherapy. Most of the current approaches focus on increasing the potency of cytokines, but another important goal is to reduce toxicity. Cytokine engineering is promising for cancer immunotherapy as it can enhance tumor targeting while minimizing adverse effects.PMID:38190116 | DOI:10.1158/1078-0432.CCR-23-1160
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research